
TTRX Stock Forecast & Price Target
TTRX Analyst Ratings
Bulls say
Turn Therapeutics is a platform dermatology company with multiple potential treatments for inflammatory and infectious skin diseases, backed by its proprietary PermaFusion technology. Its ongoing clinical study for GX-03 as a topical treatment for moderate-to-severe eczema follows promising preclinical evidence and a history of favorable tolerability for the same formula. With revision of assumptions accounting for a longer therapeutic course and a higher assumed price per course for onychomycosis, the company's overall long-term revenue contribution and forward-looking price target remain stable at $8.00.
Bears say
Turn Therapeutics is heavily reliant on its proprietary platform technology, PermaFusion, to drive future growth. However, the company's financial outlook is uncertain as they recently announced a new loan agreement with Avenue Venture for up to $25M which is tied to several milestone payments and has a discounted conversion feature. This could result in significant dilution for shareholders and may cause financial strain for the company in the future. Additionally, the company's only current product in development, GX-03, is still in the early stages of clinical trials and there is no guarantee of its success in treating eczema.
This aggregate rating is based on analysts' research of Turn Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TTRX Analyst Forecast & Price Prediction
Start investing in TTRX
Order type
Buy in
Order amount
Est. shares
0 shares